'Hybrid CDMO' launched

Shilpa Medicare will formally launch a full-service ‘hybrid’ CDMO at DCAT Week 2025. This will combine discovery, clinical and commercial outsourcing services for small and large molecules and peptides, including GLP-1s, with commercially ready novel formulations for exclusive licensing. 

Oncology will be a particular therapeutic specialism. The company said that this “dual approach enables pharmaceutical companies to leverage Shilpa’s extensive expertise in oncology without the direct risks and lengthy timelines associated with development”. It currently has multiple assets in its pipeline and three late-stage products available for licensing at DCAT.  

After rapid recent growth, Shilpa has sales of over $150 million/year. It operates five R&D centres and six manufacturing facilities with total API reactor volume of 800,000L, including two for drug substance and three for drug product. The company also has platform technologies for OEB 5 high-potency compounds, ADCs, peptides and polymers.  

In peptides, Shilpa spans solid- and solution-phase synthesis and combinations of both, with peptide API capacity of 40 kg/year and 20 million units/year of fill-finish services for cartridges and devices. There is also 8,000 L of monoclonal antibody (mAb) capacity that can be doubled when a further large 200,000L microbial fermentation facility becomes operational later this year.